A new research paper titled "BCAS1 defines a heterogeneous cell population in diffuse gliomas" has been published in Oncotarget. Oligodendrocyte precursor markers have become of great interest to ...

Diffuse gliomas are malignant brain tumors and cannot be optimally examined by conventional imaging using MRI. Amino acid PET can better visualize the activity and spread of gliomas. An international ...

Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...

A dad who thought his fatigue, headaches and blurred vision were down to needing new glasses was diagnosed with a rare and ...

His wife Laura noticed the changes in her husband. He revealed: "She says it was weeks, possibly even a couple of months, of ...

In the largest ever study of its kind, an analysis of entire tumor genomes has provided the most complete picture yet of an aggressive type of brain cancer. Diffuse gliomas are aggressive brain tumors ...

Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

Diffuse midline glioma (DMG), H3K27-altered, is a lethal pediatric high-grade tumor, lacking effective treatment options, primarily depending on clinical trials. Epigenetic agent-based immunotherapy ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Modeyso for patients with H3 K27M-mutant diffuse midline glioma. The therapy showed an overall ...

DUBLIN, Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso ™ ...